GS
RCUS icon

Gilead Sciences’s Arcus Biosciences RCUS Stock Holding History

Gilead Sciences’s Portfolio RCUS Stock Details RCUS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$969M Hold
31,424,760
– – 58.76% 1
2026
Q1 		$679M Hold
31,424,760
– – 32.05% 2
2025
Q4 		$749M Hold
31,424,760
– – 38.69% 1
2025
Q3 		$427M Hold
31,424,760
– – 23.86% 3
2025
Q2 		$256M Hold
31,424,760
– – 19.98% 3
2025
Q1 		$247M Buy
31,424,760
+1,363,636
+5% +$15.8M 20.88% 3
2024
Q4 		$448M Buy
+30,061,124
New +$491M 28.86% 3

Other funds holding RCUS

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Gilead Sciences's RCUS Position: Q2 2026 in Review

Gilead Sciences held its Arcus Biosciences (RCUS) position steady in Q2 2026 at 31,424,760 shares worth $969M. The position accounts for 58.76% of the portfolio, ranked #1.

Gilead Sciences first reported a position in RCUS in Q4 2024 and has held it in 7 quarters since. 231 funds tracked by Wall St. Rank hold RCUS as of Q2 2026.

  • Gilead Sciences held 31,424,760 shares of Arcus Biosciences worth $969M as of Q2 2026.
  • Gilead Sciences left its Arcus Biosciences share count unchanged in Q2 2026.
  • Arcus Biosciences made up 58.76% of Gilead Sciences's portfolio in Q2 2026, its #1 holding.
  • Gilead Sciences first reported a position in Arcus Biosciences in Q4 2024 and has held it in 7 quarters since.
  • 231 funds tracked by Wall St. Rank held Arcus Biosciences as of Q2 2026.

Based on Gilead Sciences's 13F filing for Q2 2026, filed 3 Aug 2026.